Gilead and Kite nab another approval for Tecartus, as leading CAR-T portfolio continues to grow

Gilead and Kite took another step Friday toward expanding their franchise of CAR-T drugs, nabbing a new approval for Tecartus.

The FDA OK’ed the therapy for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, Gilead announced Friday. It’s the drug’s second indication after Gilead initially launched the...

Click to view original post